Allogeneic stem cell transplantation for thalassemia major in India
Allogeneic stem cell transplantation (allo-SCT) is the only currently available curative treatment for thalassemia major. Since it was first done in 1981, several thousand patients have benefited from it and it is now possible to offer this treatment in different parts of the world with good results...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Vikram Mathews [verfasserIn] Poonkuzhali Balasubramanian [verfasserIn] Aby Abraham [verfasserIn] Biju George [verfasserIn] Alok Srivastava [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Pediatric Hematology Oncology Journal - Elsevier, 2017, 2(2017), 4, Seite 114-120 |
|---|---|
| Übergeordnetes Werk: |
volume:2 ; year:2017 ; number:4 ; pages:114-120 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.phoj.2018.02.001 |
|---|
| Katalog-ID: |
DOAJ017739764 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ017739764 | ||
| 003 | DE-627 | ||
| 005 | 20230502210450.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phoj.2018.02.001 |2 doi | |
| 035 | |a (DE-627)DOAJ017739764 | ||
| 035 | |a (DE-599)DOAJ3c55b34e04914e1a83fe1bbb9fed7216 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RJ1-570 | |
| 100 | 0 | |a Vikram Mathews |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Allogeneic stem cell transplantation for thalassemia major in India |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Allogeneic stem cell transplantation (allo-SCT) is the only currently available curative treatment for thalassemia major. Since it was first done in 1981, several thousand patients have benefited from it and it is now possible to offer this treatment in different parts of the world with good results. With better risk stratification and supportive care, the results of allo-SCT are now very good even in high risk patients who have significant iron overload related organ dysfunction. The improvements have mainly been in the conditioning strategies with less toxic myeloablation and management of the complications of SCT. However, several challenges remain. Transplant related complications still cause significant morbidity and mortality. There is data to show that the results of transplantation as best if done in well transfused and chelated patients <7 years of age. As only a third of the patients will have a matched related donor, there is need for investigating SCT with alternative donors. Experience with SCT for thalassemia major from matched unrelated donors or haplo-identical donors is still limited but needs further exploration. Adequate management needs to be provided post-SCT for all pre-existing complications particularly iron chelation to prevent further organ dysfunction. Systematic follow-up is needed to measure long term outcomes. The biggest challenges in India are the cost of this treatment and access to centres capable of providing this treatment. With greater support from the government, health insurance and philanthropic programs, there has been a rapid increase in the number of SCTs for thalassemia major in India. The number centres providing this treatment are also increasing making this curative treatment more widely available in India. | ||
| 650 | 4 | |a Thalassemia major | |
| 650 | 4 | |a Allogeneic stem cell transplant | |
| 650 | 4 | |a Conditioning regimens | |
| 650 | 4 | |a Regimen related toxicity | |
| 650 | 4 | |a Alternative donors | |
| 653 | 0 | |a Pediatrics | |
| 700 | 0 | |a Poonkuzhali Balasubramanian |e verfasserin |4 aut | |
| 700 | 0 | |a Aby Abraham |e verfasserin |4 aut | |
| 700 | 0 | |a Biju George |e verfasserin |4 aut | |
| 700 | 0 | |a Alok Srivastava |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Pediatric Hematology Oncology Journal |d Elsevier, 2017 |g 2(2017), 4, Seite 114-120 |w (DE-627)1760593656 |x 24681245 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2017 |g number:4 |g pages:114-120 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.phoj.2018.02.001 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/3c55b34e04914e1a83fe1bbb9fed7216 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S2468124517300979 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2468-1245 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2017 |e 4 |h 114-120 | ||
| author_variant |
v m vm p b pb a a aa b g bg a s as |
|---|---|
| matchkey_str |
article:24681245:2017----::loeectmelrnpattofrhls |
| hierarchy_sort_str |
2017 |
| callnumber-subject-code |
RJ |
| publishDate |
2017 |
| allfields |
10.1016/j.phoj.2018.02.001 doi (DE-627)DOAJ017739764 (DE-599)DOAJ3c55b34e04914e1a83fe1bbb9fed7216 DE-627 ger DE-627 rakwb eng RJ1-570 Vikram Mathews verfasserin aut Allogeneic stem cell transplantation for thalassemia major in India 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Allogeneic stem cell transplantation (allo-SCT) is the only currently available curative treatment for thalassemia major. Since it was first done in 1981, several thousand patients have benefited from it and it is now possible to offer this treatment in different parts of the world with good results. With better risk stratification and supportive care, the results of allo-SCT are now very good even in high risk patients who have significant iron overload related organ dysfunction. The improvements have mainly been in the conditioning strategies with less toxic myeloablation and management of the complications of SCT. However, several challenges remain. Transplant related complications still cause significant morbidity and mortality. There is data to show that the results of transplantation as best if done in well transfused and chelated patients <7 years of age. As only a third of the patients will have a matched related donor, there is need for investigating SCT with alternative donors. Experience with SCT for thalassemia major from matched unrelated donors or haplo-identical donors is still limited but needs further exploration. Adequate management needs to be provided post-SCT for all pre-existing complications particularly iron chelation to prevent further organ dysfunction. Systematic follow-up is needed to measure long term outcomes. The biggest challenges in India are the cost of this treatment and access to centres capable of providing this treatment. With greater support from the government, health insurance and philanthropic programs, there has been a rapid increase in the number of SCTs for thalassemia major in India. The number centres providing this treatment are also increasing making this curative treatment more widely available in India. Thalassemia major Allogeneic stem cell transplant Conditioning regimens Regimen related toxicity Alternative donors Pediatrics Poonkuzhali Balasubramanian verfasserin aut Aby Abraham verfasserin aut Biju George verfasserin aut Alok Srivastava verfasserin aut In Pediatric Hematology Oncology Journal Elsevier, 2017 2(2017), 4, Seite 114-120 (DE-627)1760593656 24681245 nnns volume:2 year:2017 number:4 pages:114-120 https://doi.org/10.1016/j.phoj.2018.02.001 kostenfrei https://doaj.org/article/3c55b34e04914e1a83fe1bbb9fed7216 kostenfrei http://www.sciencedirect.com/science/article/pii/S2468124517300979 kostenfrei https://doaj.org/toc/2468-1245 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 2 2017 4 114-120 |
| spelling |
10.1016/j.phoj.2018.02.001 doi (DE-627)DOAJ017739764 (DE-599)DOAJ3c55b34e04914e1a83fe1bbb9fed7216 DE-627 ger DE-627 rakwb eng RJ1-570 Vikram Mathews verfasserin aut Allogeneic stem cell transplantation for thalassemia major in India 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Allogeneic stem cell transplantation (allo-SCT) is the only currently available curative treatment for thalassemia major. Since it was first done in 1981, several thousand patients have benefited from it and it is now possible to offer this treatment in different parts of the world with good results. With better risk stratification and supportive care, the results of allo-SCT are now very good even in high risk patients who have significant iron overload related organ dysfunction. The improvements have mainly been in the conditioning strategies with less toxic myeloablation and management of the complications of SCT. However, several challenges remain. Transplant related complications still cause significant morbidity and mortality. There is data to show that the results of transplantation as best if done in well transfused and chelated patients <7 years of age. As only a third of the patients will have a matched related donor, there is need for investigating SCT with alternative donors. Experience with SCT for thalassemia major from matched unrelated donors or haplo-identical donors is still limited but needs further exploration. Adequate management needs to be provided post-SCT for all pre-existing complications particularly iron chelation to prevent further organ dysfunction. Systematic follow-up is needed to measure long term outcomes. The biggest challenges in India are the cost of this treatment and access to centres capable of providing this treatment. With greater support from the government, health insurance and philanthropic programs, there has been a rapid increase in the number of SCTs for thalassemia major in India. The number centres providing this treatment are also increasing making this curative treatment more widely available in India. Thalassemia major Allogeneic stem cell transplant Conditioning regimens Regimen related toxicity Alternative donors Pediatrics Poonkuzhali Balasubramanian verfasserin aut Aby Abraham verfasserin aut Biju George verfasserin aut Alok Srivastava verfasserin aut In Pediatric Hematology Oncology Journal Elsevier, 2017 2(2017), 4, Seite 114-120 (DE-627)1760593656 24681245 nnns volume:2 year:2017 number:4 pages:114-120 https://doi.org/10.1016/j.phoj.2018.02.001 kostenfrei https://doaj.org/article/3c55b34e04914e1a83fe1bbb9fed7216 kostenfrei http://www.sciencedirect.com/science/article/pii/S2468124517300979 kostenfrei https://doaj.org/toc/2468-1245 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 2 2017 4 114-120 |
| allfields_unstemmed |
10.1016/j.phoj.2018.02.001 doi (DE-627)DOAJ017739764 (DE-599)DOAJ3c55b34e04914e1a83fe1bbb9fed7216 DE-627 ger DE-627 rakwb eng RJ1-570 Vikram Mathews verfasserin aut Allogeneic stem cell transplantation for thalassemia major in India 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Allogeneic stem cell transplantation (allo-SCT) is the only currently available curative treatment for thalassemia major. Since it was first done in 1981, several thousand patients have benefited from it and it is now possible to offer this treatment in different parts of the world with good results. With better risk stratification and supportive care, the results of allo-SCT are now very good even in high risk patients who have significant iron overload related organ dysfunction. The improvements have mainly been in the conditioning strategies with less toxic myeloablation and management of the complications of SCT. However, several challenges remain. Transplant related complications still cause significant morbidity and mortality. There is data to show that the results of transplantation as best if done in well transfused and chelated patients <7 years of age. As only a third of the patients will have a matched related donor, there is need for investigating SCT with alternative donors. Experience with SCT for thalassemia major from matched unrelated donors or haplo-identical donors is still limited but needs further exploration. Adequate management needs to be provided post-SCT for all pre-existing complications particularly iron chelation to prevent further organ dysfunction. Systematic follow-up is needed to measure long term outcomes. The biggest challenges in India are the cost of this treatment and access to centres capable of providing this treatment. With greater support from the government, health insurance and philanthropic programs, there has been a rapid increase in the number of SCTs for thalassemia major in India. The number centres providing this treatment are also increasing making this curative treatment more widely available in India. Thalassemia major Allogeneic stem cell transplant Conditioning regimens Regimen related toxicity Alternative donors Pediatrics Poonkuzhali Balasubramanian verfasserin aut Aby Abraham verfasserin aut Biju George verfasserin aut Alok Srivastava verfasserin aut In Pediatric Hematology Oncology Journal Elsevier, 2017 2(2017), 4, Seite 114-120 (DE-627)1760593656 24681245 nnns volume:2 year:2017 number:4 pages:114-120 https://doi.org/10.1016/j.phoj.2018.02.001 kostenfrei https://doaj.org/article/3c55b34e04914e1a83fe1bbb9fed7216 kostenfrei http://www.sciencedirect.com/science/article/pii/S2468124517300979 kostenfrei https://doaj.org/toc/2468-1245 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 2 2017 4 114-120 |
| allfieldsGer |
10.1016/j.phoj.2018.02.001 doi (DE-627)DOAJ017739764 (DE-599)DOAJ3c55b34e04914e1a83fe1bbb9fed7216 DE-627 ger DE-627 rakwb eng RJ1-570 Vikram Mathews verfasserin aut Allogeneic stem cell transplantation for thalassemia major in India 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Allogeneic stem cell transplantation (allo-SCT) is the only currently available curative treatment for thalassemia major. Since it was first done in 1981, several thousand patients have benefited from it and it is now possible to offer this treatment in different parts of the world with good results. With better risk stratification and supportive care, the results of allo-SCT are now very good even in high risk patients who have significant iron overload related organ dysfunction. The improvements have mainly been in the conditioning strategies with less toxic myeloablation and management of the complications of SCT. However, several challenges remain. Transplant related complications still cause significant morbidity and mortality. There is data to show that the results of transplantation as best if done in well transfused and chelated patients <7 years of age. As only a third of the patients will have a matched related donor, there is need for investigating SCT with alternative donors. Experience with SCT for thalassemia major from matched unrelated donors or haplo-identical donors is still limited but needs further exploration. Adequate management needs to be provided post-SCT for all pre-existing complications particularly iron chelation to prevent further organ dysfunction. Systematic follow-up is needed to measure long term outcomes. The biggest challenges in India are the cost of this treatment and access to centres capable of providing this treatment. With greater support from the government, health insurance and philanthropic programs, there has been a rapid increase in the number of SCTs for thalassemia major in India. The number centres providing this treatment are also increasing making this curative treatment more widely available in India. Thalassemia major Allogeneic stem cell transplant Conditioning regimens Regimen related toxicity Alternative donors Pediatrics Poonkuzhali Balasubramanian verfasserin aut Aby Abraham verfasserin aut Biju George verfasserin aut Alok Srivastava verfasserin aut In Pediatric Hematology Oncology Journal Elsevier, 2017 2(2017), 4, Seite 114-120 (DE-627)1760593656 24681245 nnns volume:2 year:2017 number:4 pages:114-120 https://doi.org/10.1016/j.phoj.2018.02.001 kostenfrei https://doaj.org/article/3c55b34e04914e1a83fe1bbb9fed7216 kostenfrei http://www.sciencedirect.com/science/article/pii/S2468124517300979 kostenfrei https://doaj.org/toc/2468-1245 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 2 2017 4 114-120 |
| allfieldsSound |
10.1016/j.phoj.2018.02.001 doi (DE-627)DOAJ017739764 (DE-599)DOAJ3c55b34e04914e1a83fe1bbb9fed7216 DE-627 ger DE-627 rakwb eng RJ1-570 Vikram Mathews verfasserin aut Allogeneic stem cell transplantation for thalassemia major in India 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Allogeneic stem cell transplantation (allo-SCT) is the only currently available curative treatment for thalassemia major. Since it was first done in 1981, several thousand patients have benefited from it and it is now possible to offer this treatment in different parts of the world with good results. With better risk stratification and supportive care, the results of allo-SCT are now very good even in high risk patients who have significant iron overload related organ dysfunction. The improvements have mainly been in the conditioning strategies with less toxic myeloablation and management of the complications of SCT. However, several challenges remain. Transplant related complications still cause significant morbidity and mortality. There is data to show that the results of transplantation as best if done in well transfused and chelated patients <7 years of age. As only a third of the patients will have a matched related donor, there is need for investigating SCT with alternative donors. Experience with SCT for thalassemia major from matched unrelated donors or haplo-identical donors is still limited but needs further exploration. Adequate management needs to be provided post-SCT for all pre-existing complications particularly iron chelation to prevent further organ dysfunction. Systematic follow-up is needed to measure long term outcomes. The biggest challenges in India are the cost of this treatment and access to centres capable of providing this treatment. With greater support from the government, health insurance and philanthropic programs, there has been a rapid increase in the number of SCTs for thalassemia major in India. The number centres providing this treatment are also increasing making this curative treatment more widely available in India. Thalassemia major Allogeneic stem cell transplant Conditioning regimens Regimen related toxicity Alternative donors Pediatrics Poonkuzhali Balasubramanian verfasserin aut Aby Abraham verfasserin aut Biju George verfasserin aut Alok Srivastava verfasserin aut In Pediatric Hematology Oncology Journal Elsevier, 2017 2(2017), 4, Seite 114-120 (DE-627)1760593656 24681245 nnns volume:2 year:2017 number:4 pages:114-120 https://doi.org/10.1016/j.phoj.2018.02.001 kostenfrei https://doaj.org/article/3c55b34e04914e1a83fe1bbb9fed7216 kostenfrei http://www.sciencedirect.com/science/article/pii/S2468124517300979 kostenfrei https://doaj.org/toc/2468-1245 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 2 2017 4 114-120 |
| language |
English |
| source |
In Pediatric Hematology Oncology Journal 2(2017), 4, Seite 114-120 volume:2 year:2017 number:4 pages:114-120 |
| sourceStr |
In Pediatric Hematology Oncology Journal 2(2017), 4, Seite 114-120 volume:2 year:2017 number:4 pages:114-120 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Thalassemia major Allogeneic stem cell transplant Conditioning regimens Regimen related toxicity Alternative donors Pediatrics |
| isfreeaccess_bool |
true |
| container_title |
Pediatric Hematology Oncology Journal |
| authorswithroles_txt_mv |
Vikram Mathews @@aut@@ Poonkuzhali Balasubramanian @@aut@@ Aby Abraham @@aut@@ Biju George @@aut@@ Alok Srivastava @@aut@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
1760593656 |
| id |
DOAJ017739764 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ017739764</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502210450.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.phoj.2018.02.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ017739764</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3c55b34e04914e1a83fe1bbb9fed7216</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RJ1-570</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Vikram Mathews</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Allogeneic stem cell transplantation for thalassemia major in India</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Allogeneic stem cell transplantation (allo-SCT) is the only currently available curative treatment for thalassemia major. Since it was first done in 1981, several thousand patients have benefited from it and it is now possible to offer this treatment in different parts of the world with good results. With better risk stratification and supportive care, the results of allo-SCT are now very good even in high risk patients who have significant iron overload related organ dysfunction. The improvements have mainly been in the conditioning strategies with less toxic myeloablation and management of the complications of SCT. However, several challenges remain. Transplant related complications still cause significant morbidity and mortality. There is data to show that the results of transplantation as best if done in well transfused and chelated patients <7 years of age. As only a third of the patients will have a matched related donor, there is need for investigating SCT with alternative donors. Experience with SCT for thalassemia major from matched unrelated donors or haplo-identical donors is still limited but needs further exploration. Adequate management needs to be provided post-SCT for all pre-existing complications particularly iron chelation to prevent further organ dysfunction. Systematic follow-up is needed to measure long term outcomes. The biggest challenges in India are the cost of this treatment and access to centres capable of providing this treatment. With greater support from the government, health insurance and philanthropic programs, there has been a rapid increase in the number of SCTs for thalassemia major in India. The number centres providing this treatment are also increasing making this curative treatment more widely available in India.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Thalassemia major</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Allogeneic stem cell transplant</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Conditioning regimens</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Regimen related toxicity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Alternative donors</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pediatrics</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Poonkuzhali Balasubramanian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aby Abraham</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Biju George</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alok Srivastava</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pediatric Hematology Oncology Journal</subfield><subfield code="d">Elsevier, 2017</subfield><subfield code="g">2(2017), 4, Seite 114-120</subfield><subfield code="w">(DE-627)1760593656</subfield><subfield code="x">24681245</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:114-120</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.phoj.2018.02.001</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3c55b34e04914e1a83fe1bbb9fed7216</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S2468124517300979</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2468-1245</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2017</subfield><subfield code="e">4</subfield><subfield code="h">114-120</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Vikram Mathews |
| spellingShingle |
Vikram Mathews misc RJ1-570 misc Thalassemia major misc Allogeneic stem cell transplant misc Conditioning regimens misc Regimen related toxicity misc Alternative donors misc Pediatrics Allogeneic stem cell transplantation for thalassemia major in India |
| authorStr |
Vikram Mathews |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760593656 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RJ1-570 |
| illustrated |
Not Illustrated |
| issn |
24681245 |
| topic_title |
RJ1-570 Allogeneic stem cell transplantation for thalassemia major in India Thalassemia major Allogeneic stem cell transplant Conditioning regimens Regimen related toxicity Alternative donors |
| topic |
misc RJ1-570 misc Thalassemia major misc Allogeneic stem cell transplant misc Conditioning regimens misc Regimen related toxicity misc Alternative donors misc Pediatrics |
| topic_unstemmed |
misc RJ1-570 misc Thalassemia major misc Allogeneic stem cell transplant misc Conditioning regimens misc Regimen related toxicity misc Alternative donors misc Pediatrics |
| topic_browse |
misc RJ1-570 misc Thalassemia major misc Allogeneic stem cell transplant misc Conditioning regimens misc Regimen related toxicity misc Alternative donors misc Pediatrics |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Pediatric Hematology Oncology Journal |
| hierarchy_parent_id |
1760593656 |
| hierarchy_top_title |
Pediatric Hematology Oncology Journal |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760593656 |
| title |
Allogeneic stem cell transplantation for thalassemia major in India |
| ctrlnum |
(DE-627)DOAJ017739764 (DE-599)DOAJ3c55b34e04914e1a83fe1bbb9fed7216 |
| title_full |
Allogeneic stem cell transplantation for thalassemia major in India |
| author_sort |
Vikram Mathews |
| journal |
Pediatric Hematology Oncology Journal |
| journalStr |
Pediatric Hematology Oncology Journal |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
txt |
| container_start_page |
114 |
| author_browse |
Vikram Mathews Poonkuzhali Balasubramanian Aby Abraham Biju George Alok Srivastava |
| container_volume |
2 |
| class |
RJ1-570 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Vikram Mathews |
| doi_str_mv |
10.1016/j.phoj.2018.02.001 |
| author2-role |
verfasserin |
| title_sort |
allogeneic stem cell transplantation for thalassemia major in india |
| callnumber |
RJ1-570 |
| title_auth |
Allogeneic stem cell transplantation for thalassemia major in India |
| abstract |
Allogeneic stem cell transplantation (allo-SCT) is the only currently available curative treatment for thalassemia major. Since it was first done in 1981, several thousand patients have benefited from it and it is now possible to offer this treatment in different parts of the world with good results. With better risk stratification and supportive care, the results of allo-SCT are now very good even in high risk patients who have significant iron overload related organ dysfunction. The improvements have mainly been in the conditioning strategies with less toxic myeloablation and management of the complications of SCT. However, several challenges remain. Transplant related complications still cause significant morbidity and mortality. There is data to show that the results of transplantation as best if done in well transfused and chelated patients <7 years of age. As only a third of the patients will have a matched related donor, there is need for investigating SCT with alternative donors. Experience with SCT for thalassemia major from matched unrelated donors or haplo-identical donors is still limited but needs further exploration. Adequate management needs to be provided post-SCT for all pre-existing complications particularly iron chelation to prevent further organ dysfunction. Systematic follow-up is needed to measure long term outcomes. The biggest challenges in India are the cost of this treatment and access to centres capable of providing this treatment. With greater support from the government, health insurance and philanthropic programs, there has been a rapid increase in the number of SCTs for thalassemia major in India. The number centres providing this treatment are also increasing making this curative treatment more widely available in India. |
| abstractGer |
Allogeneic stem cell transplantation (allo-SCT) is the only currently available curative treatment for thalassemia major. Since it was first done in 1981, several thousand patients have benefited from it and it is now possible to offer this treatment in different parts of the world with good results. With better risk stratification and supportive care, the results of allo-SCT are now very good even in high risk patients who have significant iron overload related organ dysfunction. The improvements have mainly been in the conditioning strategies with less toxic myeloablation and management of the complications of SCT. However, several challenges remain. Transplant related complications still cause significant morbidity and mortality. There is data to show that the results of transplantation as best if done in well transfused and chelated patients <7 years of age. As only a third of the patients will have a matched related donor, there is need for investigating SCT with alternative donors. Experience with SCT for thalassemia major from matched unrelated donors or haplo-identical donors is still limited but needs further exploration. Adequate management needs to be provided post-SCT for all pre-existing complications particularly iron chelation to prevent further organ dysfunction. Systematic follow-up is needed to measure long term outcomes. The biggest challenges in India are the cost of this treatment and access to centres capable of providing this treatment. With greater support from the government, health insurance and philanthropic programs, there has been a rapid increase in the number of SCTs for thalassemia major in India. The number centres providing this treatment are also increasing making this curative treatment more widely available in India. |
| abstract_unstemmed |
Allogeneic stem cell transplantation (allo-SCT) is the only currently available curative treatment for thalassemia major. Since it was first done in 1981, several thousand patients have benefited from it and it is now possible to offer this treatment in different parts of the world with good results. With better risk stratification and supportive care, the results of allo-SCT are now very good even in high risk patients who have significant iron overload related organ dysfunction. The improvements have mainly been in the conditioning strategies with less toxic myeloablation and management of the complications of SCT. However, several challenges remain. Transplant related complications still cause significant morbidity and mortality. There is data to show that the results of transplantation as best if done in well transfused and chelated patients <7 years of age. As only a third of the patients will have a matched related donor, there is need for investigating SCT with alternative donors. Experience with SCT for thalassemia major from matched unrelated donors or haplo-identical donors is still limited but needs further exploration. Adequate management needs to be provided post-SCT for all pre-existing complications particularly iron chelation to prevent further organ dysfunction. Systematic follow-up is needed to measure long term outcomes. The biggest challenges in India are the cost of this treatment and access to centres capable of providing this treatment. With greater support from the government, health insurance and philanthropic programs, there has been a rapid increase in the number of SCTs for thalassemia major in India. The number centres providing this treatment are also increasing making this curative treatment more widely available in India. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA |
| container_issue |
4 |
| title_short |
Allogeneic stem cell transplantation for thalassemia major in India |
| url |
https://doi.org/10.1016/j.phoj.2018.02.001 https://doaj.org/article/3c55b34e04914e1a83fe1bbb9fed7216 http://www.sciencedirect.com/science/article/pii/S2468124517300979 https://doaj.org/toc/2468-1245 |
| remote_bool |
true |
| author2 |
Poonkuzhali Balasubramanian Aby Abraham Biju George Alok Srivastava |
| author2Str |
Poonkuzhali Balasubramanian Aby Abraham Biju George Alok Srivastava |
| ppnlink |
1760593656 |
| callnumber-subject |
RJ - Pediatrics |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1016/j.phoj.2018.02.001 |
| callnumber-a |
RJ1-570 |
| up_date |
2024-07-03T13:48:34.627Z |
| _version_ |
1803565939695812610 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ017739764</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502210450.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.phoj.2018.02.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ017739764</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3c55b34e04914e1a83fe1bbb9fed7216</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RJ1-570</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Vikram Mathews</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Allogeneic stem cell transplantation for thalassemia major in India</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Allogeneic stem cell transplantation (allo-SCT) is the only currently available curative treatment for thalassemia major. Since it was first done in 1981, several thousand patients have benefited from it and it is now possible to offer this treatment in different parts of the world with good results. With better risk stratification and supportive care, the results of allo-SCT are now very good even in high risk patients who have significant iron overload related organ dysfunction. The improvements have mainly been in the conditioning strategies with less toxic myeloablation and management of the complications of SCT. However, several challenges remain. Transplant related complications still cause significant morbidity and mortality. There is data to show that the results of transplantation as best if done in well transfused and chelated patients <7 years of age. As only a third of the patients will have a matched related donor, there is need for investigating SCT with alternative donors. Experience with SCT for thalassemia major from matched unrelated donors or haplo-identical donors is still limited but needs further exploration. Adequate management needs to be provided post-SCT for all pre-existing complications particularly iron chelation to prevent further organ dysfunction. Systematic follow-up is needed to measure long term outcomes. The biggest challenges in India are the cost of this treatment and access to centres capable of providing this treatment. With greater support from the government, health insurance and philanthropic programs, there has been a rapid increase in the number of SCTs for thalassemia major in India. The number centres providing this treatment are also increasing making this curative treatment more widely available in India.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Thalassemia major</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Allogeneic stem cell transplant</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Conditioning regimens</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Regimen related toxicity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Alternative donors</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pediatrics</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Poonkuzhali Balasubramanian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aby Abraham</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Biju George</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alok Srivastava</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pediatric Hematology Oncology Journal</subfield><subfield code="d">Elsevier, 2017</subfield><subfield code="g">2(2017), 4, Seite 114-120</subfield><subfield code="w">(DE-627)1760593656</subfield><subfield code="x">24681245</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:114-120</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.phoj.2018.02.001</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3c55b34e04914e1a83fe1bbb9fed7216</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S2468124517300979</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2468-1245</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2017</subfield><subfield code="e">4</subfield><subfield code="h">114-120</subfield></datafield></record></collection>
|
| score |
7.401884 |